Skip to main content
OpenTrials
Completed

NCT Number: NCT00640367

Intra-arterial Versus Systemic Thrombolysis for Acute Ischemic Stroke

SYNTHESIS is a pragmatic multicenter randomized controlled trial (RCT), open-label, with blinded follow-up aiming to determine whether loco-regional intra-arterial (IA) with recombinant tissue-plasminogen activator (rt-PA) and/or mechanical devices, as compared with systemic intravenous (I.V.) infusion of rt-PA within 3 hours of ischemic stroke, increases the proportion of independent survivors at 3 months.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

A.O. Ospedale Ca' Granda

Milan, 20162, Italy

About this study

Eligibility criteria:patients with symptomatic, CT verified, acute ischemic stroke, being able to initiate IV rt-PA within 3 hours and IA thrombolysis within 6 hours of stroke onset, when uncertainty about appropriateness the two approaches exists as established by the treating physician.

Eligible patients are randomized to receive either 0.9 mg/kg (max 90 mg) IV rt-PA (control arm) or up to 0.9 mg/Kg IA rt-PA (max 90 mg) over 60 minutes into the thrombus, eventually associated with clot mechanical disaggregation/dislocation or retraction/aspiration. Mechanical thrombolysis is possible also without the use of rt-PA. The procedural choices of the interventional neuroradiologist depend on the type of occlusion, circumstances and experience.

The study is designed to detect or disprove (alpha=5% and power probability=80%) a 15% absolute difference between the treatment groups in the percentage of patients with a favourable outcome (Modified Rankin Scale Score = 0-1).Enrollment will be completed with 350 randomized patients.

Neurological deficit will be scored with NIH Stroke Scale at day 7 or discharge, or transfer to another hospital, whichever occurs first.Patient's clinical condition will be again evaluated by a telephone call after 90 days.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sudden focal neurological deficit attributable to a stroke
  • Clearly defined time of onset, allowing initiation of intravenous treatment within 3 hours of symptoms onset and intra-arterial treatment within 6 hour of symptoms onset.
  • Age greater than 18 years

Exclusion criteria

  • Disability preceding stroke consistent with a modified Rankin scale score of 2-4
  • Coma at onset
  • Rapidly improving neurological deficit
  • Seizure at onset
  • Clinical presentation suggestive of a subarachnoid hemorrhage
  • Previous history of intracranial hemorrhage
  • Septic embolism
  • Arterial puncture at a non compressible site within the previous 7 days
  • Any traumatic brain injury within the previous 14 days
  • Surgery of the central nervous system in the previous 3 months
  • Gastrointestinal hemorrhage or urinary tract hemorrhage within the previous 14 days.
  • Current therapy with intravenous or subcutaneous heparin to rise the clotting time
  • Known hereditary or acquired hemorrhagic diathesis, baseline INR greater than 1.5, aPTT more than 1.5 times normal, or baseline platelet count less than 100,000 per cubic millimeter
  • Baseline blood glucose concentrations below 2.75 mm/L (50 mg/dL).
  • Known contrast sensitivity.
  • Women of childbearing potential (unless pregnancy impossible) or known to be breastfeeding. Uncontrolled hypertension defined by a blood pressure greater or equal 185 mmHg systolic or diastolic greater or equal 110 mm Hg in 3 separate occasions at least 10 minutes apart or requiring continuous IV therapy.
  • Prognosis very poor regardless of therapy; likely to be dead within months.
  • Unlikely to be available for follow-up (eg, no fixed home address, visitor from overseas).
  • Any other condition which local investigators feels would pose a significant hazard in terms of risk/benefit to the patient, or if therapies are impracticable.

COMPUTED TOMOGRAPHIC (CT) SCAN EXCLUSION CRITERIA

  • Intracranial tumors except small meningioma
  • Hemorrhage of any degree
  • Acute infarction (since this may be an indicator that the time of onset is uncorrected)

Treatment and study plan

Alteplase IA and/or mechanical thrombolysis

Other

loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis

Alteplase IV

Drug

intravenous recombinant tissue plasminogen activator

Primary outcomes

  1. To assess whether IA thrombolysis, as compared to IV rt-PA, increases survival free of disability (modified Rankin score of zero or 1) at 3 months.

    Time frame: 3 months

Secondary outcomes

  1. To asses whether IA thrombolysis vs.IV rt-PA 1.improves the 7 day neurological deficit; 2.is safe on the base of symptomatic intracranial hemorrhages, fatal and non-fatal stroke, death from any cause, neurological deterioration within 7 days

    Time frame: 7 days

Sponsors and collaborators

Lead sponsor

Niguarda Hospital

Other

Registry information

Official study title

Synthesis Expansion: A Randomized Controlled Trial on Intra-Arterial Versus Intravenous Thrombolysis in Acute Ischemic Stroke

Acronym: SYNTHESIS EXP

Important dates

Study start
2008
Primary completion
2009
Study completion
2012
First posted
Mar 21, 2008
Registry last updated
Apr 25, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.